Skip to main content

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Written by: Editor
Published on: 16 Apr 2024

Telix PharmaceuticalsMelbourne (Australia) | 16 April 2024

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™218F-floretyrosine or 18F-FET). 

The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). Concurrently, Telix is in the final stages of preparing its U.S. New Drug Application (NDA) for TLX101-CDx in this initial indication, in both adult and paediatric patients. This designation enables expedited review and closer consultation with the FDA during the review process.  

Amino acid PET is currently included in U.S. and European guidelines for the imaging of gliomas3, however there is no FDA-approved targeted PET agent for brain cancer imaging in the U.S. Telix’s goal is to make this product commercially available in the U.S., significantly increasing patient access to this important imaging agent. 

Collaboration with the University of California, San Francisco  

Telix has an exclusive research collaboration and data license agreement with the University of California, San Francisco (UCSF). UCSF is one of the leading academic centres conducting clinical research into the use of FET PET4 in a variety of neurological malignancies. This academic-industrial collaboration supporting joint development and commercialisation will enable Telix to offer TLX101-CDx access as a commercial product in the U.S., subject to regulatory approval. 

Thomas A. Hope, MD, Professor of Radiology at UCSF, said, “There is critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting, and we are excited to leverage the clinical experience at UCSF to help make this investigational agent more widely available. 18F-FET has the potential to help determine if a glioma is truly progressing or undergoing a treatment-induced change, known as pseudo-progression, where MRI5 – the standard of care – can often be inconclusive.” 

David N. Cade, MD, Group Chief Medical Officer at Telix, stated, “This unique collaboration between Dr. Hope’s team at UCSF and Telix will enable us to utilise our collective clinical data and expertise to facilitate nationwide access to FET PET in the United States while fostering ongoing research and development with the objective of expanding the clinical utility of this advanced imaging agent for the benefit of patients.”  

Commercial Partnership: PharmaLogic Holdings Corp 

Telix has selected PharmaLogic Holdings Corp (PharmaLogic) as its commercial manufacturing and pharmacy distribution partner, to supply finished unit doses of TLX101-CDx to the U.S. market.  

Steven Chilinski, President and CEO at PharmaLogic, added, “Telix has quickly grown into a global theranostics leader with an impressive product pipeline. Through this partnership, we’re delighted to bring this imaging agent to glioma patients in the U.S. upon regulatory approval.”  

Richard Valeix, Group Chief Commercial Officer at Telix, continued, “These milestones represent significant progress as we bring this investigational product closer to market in the U.S. and commercial launch. PharmaLogic has rapidly developed an excellent reputation for manufacturing radiopharmaceuticals to rigorous quality standards and will deliver a key component of Telix’s supply chain strategy for TLX101-CDx in the U.S., subject to regulatory approval.” 

About TLX101-CDx 

TLX101-CDx (Pixclara™2) is a PET imaging agent, which has been previously granted orphan drug designation (ODD) in the U.S. as an imaging agent for the management of glioma6. TLX101-CDx targets membrane transport proteins known as LAT1 and LAT27. This enables TLX101-CDx to be potentially utilised as a companion diagnostic agent to TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA), Telix’s LAT1-targeting investigational glioblastoma (GBM) therapy, currently under investigation in the and IPAX-28 and IPAX-Linz9 studies. TLX101 and TLX101-CDx have not received marketing authorisations in any jurisdiction.

Read the full ASX release here


  1. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. More: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.  ↩︎
  2.  Brand name subject to final regulatory approval.  ↩︎
  3. Joint European Association of Nuclear Medicine//European Association of Neurooncology/Response Assessment in Neurooncology practice guidelines/Society for Nuclear Medicine and Molecular Imaging procedure standards for the clinical use of PET imaging in gliomas.  ↩︎
  4. Positron emission tomography with 18F-floretyrosine. ↩︎
  5. Magnetic resonance imaging ↩︎
  6. Telix ASX disclosure 6 October 2020.  ↩︎
  7. Large amino acid transporters 1 and 2.  ↩︎
  8. Telix media release 8 August 2023. ClinicalTrials.gov ID: NCT05450744.  ↩︎
  9. Telix media release 22 November 2022.  ↩︎